伏欣奇拜单抗(Genakumab) - 药物靶点：IL-1β_在研适应症：痛风性关节炎，全身型幼年特发性关节炎，非感染性后葡萄膜炎_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Firsekibart、Kinnazumab、金纳单抗

+ [3]

靶点

IL-1β

作用方式

抑制剂

作用机制

IL-1β抑制剂(白细胞介素-1β抑制剂)

治疗领域

免疫系统疾病遗传病与畸形内分泌与代谢疾病+ [5]

在研适应症

痛风性关节炎全身型幼年特发性关节炎非感染性后葡萄膜炎+ [6]

非在研适应症

晚期恶性实体瘤原发性痛风

原研机构

长春金赛药业有限责任公司

在研机构

长春金赛药业有限责任公司

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

中国 (2025-06-30),

痛风性关节炎

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 1188682110H

来源: *****

Sequence Code 1188682113L

来源: *****

关联

24

项与伏欣奇拜单抗相关的临床试验

NCT07547995

/ Not yet recruiting临床2期

A Phase II Clinical Study to Assess the Efficacy and Safety of GenSci048 in Subjects With Active Non-infectious Uveitis.

This study is designed to evaluate the efficacy and safety of GenSci048 compared with placebo in subjects with active non-infectious uveitis.

开始日期2026-06-18

申办/合作机构

长春金赛药业有限责任公司

NCT07502105

/ Not yet recruitingN/AIIT

A Single-Centre, Single-Arm Study on the Efficacy and Safety of Firsekibart in the Treatment of Systemic Sclerosis

This study is a single-center, single-arm, open-label, exploratory clinical trial. A total of 30 patients with diffuse cutaneous systemic sclerosis (dcSSc) will be enrolled. A historical control cohort will be established to evaluate the efficacy and safety of Firsekibart by comparing with historical data.

开始日期2026-05-01

申办/合作机构

华中科技大学同济医学院附属同济医院

NCT07535840

/ Not yet recruitingN/AIIT

A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma

This study aims to evaluate the effectiveness and safety of a combination therapy with Fuxinqibai monoclonal antibody, Tislelizumab, and Lenvatinib in patients with advanced, unresectable TP53-mutated hepatocellular carcinoma (HCC) who have previously failed systemic immunotherapy.
Eligible patients will receive:
Fuxinqibai 200 mg IV every 3 weeks Tislelizumab 200 mg IV every 3 weeks Lenvatinib 8 mg (≤60 kg) or 12 mg (>60 kg) orally once daily Treatment will continue until disease progression, unacceptable toxicity, start of a new anticancer therapy, withdrawal of consent, or other protocol-defined reasons. Tumor response will be evaluated by RECIST v1.1 every 6 weeks, and confirmed after 4 weeks if response is observed.
Safety will be monitored through adverse events and laboratory tests, graded according to NCI CTCAE v5.0. After treatment ends, patients will be followed every 6 weeks for tumor assessment and every 12 weeks for survival, until death, loss to follow-up, or withdrawal of consent.
Primary Objective: To assess the objective response rate (ORR) of the combination therapy.
Secondary Objectives: To evaluate overall efficacy, safety, and explore potential biomarkers predicting treatment response.

开始日期2026-05-01

申办/合作机构-

100 项与伏欣奇拜单抗相关的临床结果

登录后查看更多信息

100 项与伏欣奇拜单抗相关的转化医学

登录后查看更多信息

100 项与伏欣奇拜单抗相关的专利（医药）

登录后查看更多信息

4

项与伏欣奇拜单抗相关的文献（医药）

2026-02-01·Clinical Pharmacology in Drug Development

A Randomized, Double‐Blind, Placebo‐Controlled, Multiple Ascending Dose Phase 1 Study of Firsekibart in Chinese Healthy Participants

Article

作者: Yong, Xiaolan ; Li, Xiao ; Xu, Qian ; Luo, Tianhong ; Chen, Yushi ; Zhu, Xiaoyan ; Du, Xiaolin

Abstract:

Firsekibart is an anti‐IL‐1β monoclonal antibody for treating acute gout flares in adults. This randomized, double‐blind, placebo‐controlled study assessed the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of multiple ascending doses of firsekibart in healthy Chinese adults. Participants were assigned to one of the two firsekibart cohorts (120 or 200 mg) every 4 weeks for three doses and randomized in a 5:1 ratio to receive firsekibart or placebo. Twenty‐four participants completed the study. After a single dose, the median T max was 7.0 days for both firsekibart groups. Mean C max was 16.0 and 29.2 µg/mL; AUC 0–t was 350.6 and 600.0 d·µg/mL for the 120 and 200 mg groups. Following multiple doses, the median T max,ss was 4.0 days and 5.5 days, C max,ss was 31.5 and 54.1 µg/mL, AUC 0–t,ss was 1213.3 and 1975.8 d·µg/mL, and AUC 0–∞,ss was 1445.3 and 2355.4 d·µg/mL. Accumulation ratios for C max and AUC were <2 in both groups. Serum total IL‐1β levels showed no dose‐related trends and immunogenicity was low. Treatment‐emergent adverse events (TEAEs) occurred in 65.0% of firsekibart‐treated participants and 75.0% of placebo‐treated participants. TEAEs were mostly grade 1 or 2. Firsekibart was safe, well tolerated after multiple administrations in healthy participants, with dose‐proportional exposure and modest accumulation.

2025-09-01·ADVANCES IN THERAPY

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Firsekibart, an Anti-interleukin-1β Monoclonal Antibody, in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

Article

作者: Luo, Tianhong ; Zhu, Xiaoyan ; Tian, Wei ; Chen, Rui ; Xu, Qian ; Liu, Hongzhong ; Yuan, Yuping

INTRODUCTION:

The pro-inflammatory cytokine interleukin-1β (IL-1β) is an important therapeutic target for treating autoinflammatory diseases. Firsekibart is a high affinity, fully human monoclonal antibody targeting IL-1β, which selectively binds to and neutralizes IL-1β. Here, we investigated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of firsekibart administered as a single-dose, subcutaneous injection in healthy Chinese participants.

METHODS:

This first-in-human, double-blind, phase 1 trial of firsekibart included healthy Chinese participants (≥ 18 to ≤ 50 years old) divided into five dose-escalated groups: 0.3, 1.0, 2.0, 4.0, and 6.0 mg/kg. In each group, participants were randomized in a 3:1 ratio to receive firsekibart or placebo. The primary endpoint was the safety and tolerability, primarily assessed by monitoring adverse events (AEs). Secondary endpoints included the evaluation of immunogenicity, PK, and PD.

RESULTS:

A total of 40 participants were enrolled in the study, receiving either firsekibart (n = 30) or placebo (n = 10); all participants completed the study. Treatment-emergent AEs (TEAEs) occurred in 86.7% of participants receiving firsekibart and 90.0% receiving placebo. There were no reports of grade ≥ 3 TEAEs, serious AEs, or TEAEs leading to study withdrawal or death. The incidence of TEAEs in the firsekibart group was not dose dependent. No PK/PD changes or safety events related to immunogenicity were observed. Serum concentration of firsekibart at each sampling timepoint increased proportionally with dose (0.3-6.0 mg/kg). The area under the concentration-time curve from zero to infinity (AUC_0-∞) showed a linear relationship with the dose of firsekibart. Overall, there were no treatment or dose-related trends observed in PD parameters, and no significant correlation was found between PK parameters and total serum IL-1β levels.

CONCLUSION:

Firsekibart had an acceptable safety profile and was well tolerated in healthy Chinese participants across all investigated doses, supporting future investigation of firsekibart as a potential treatment option for inflammatory diseases.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT04337437 (retrospectively registered on April 7, 2020).

2025-08-01·The Innovation

Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trial

Article

作者: Li, Rongbin ; Qi, Chuang ; Li, Rongping ; Duan, Xinwang ; Yu, Jing ; Li, Yi ; Xue, Yu ; Lian, Yuling ; Qian, Long ; Gou, Wei ; Li, Juan ; Zou, Hejian ; Zhang, Xu ; Duan, Lihua ; Zhang, Ning ; Hu, Jiankang ; Chu, Tianshu ; Huang, Dongzhe

This phase 3 trial evaluated the efficacy and safety of Firsekibart, a novel, fully human anti-interleukin-1β monoclonal antibody, in patients with frequent acute gout flares unsuitable for standard therapy. Patients were randomized (1:1, stratified by baseline pain visual analog scale [VAS]) to the Firsekibart (200 mg) or compound betamethasone (CB; 7 mg) group. Co-primary endpoints included change in pain intensity in the target joint at 72 h (non-inferiority testing) and time to first new flare within 12 weeks (superiority testing). The non-inferiority margin was 10 mm. The full analysis set included 311 patients (Firsekibart: N = 156; CB: N = 155). At 72 h, the least squares mean change in pain VAS scores from baseline was -57.09 mm (95% confidence interval [CI]: -60.08 to -54.10) for Firsekibart and -53.77 mm (95% CI: -56.77 to -50.77) for CB, with treatment difference of -3.32 mm (95% CI: -7.56 to 0.91), establishing non-inferiority. The median time to first new flare was not reached within 12 weeks in the Firsekibart group compared with 45.0 days (95% CI: 28.00 to 63.00) in the CB group. Firsekibart significantly reduced the risk of new flare by 90% vs. CB (hazard ratio: 0.10; 95% CI: 0.06 to 0.17; stratified log rank p < 0.0001). Efficacy was consistent across subgroups. Treatment-emergent adverse events occurred in 71.2% of Firsekibart-treated patients and 69.9% of those receiving CB. In conclusion, Firsekibart is effective and well tolerated for acute gout flares in patients unsuitable for standard therapy, demonstrating non-inferiority in rapid pain relief and significant superiority in preventing flare compared with CB.

1,150

项与伏欣奇拜单抗相关的新闻（医药）

19 小时之前

·国家药品监督管理局

国家药监局批准伏欣奇拜单抗注射液上市

索引号 XZXK-2026-10078 主题分类工作动态标题国家药监局批准伏欣奇拜单抗注射液上市发布日期 2026-04-30　　近日，国家药品监督管理局批准长春金赛药业有限责任公司申报的伏欣奇拜单抗注射液（商品名：金蓓欣）上市，用于对非甾体类抗炎药和/或秋水仙碱禁忌、不耐受或缺乏疗效的，以及不适合反复使用类固醇激素的成人痛风性关节炎急性发作。该品种的上市为相关患者提供了新的治疗选择。

上市批准

19 小时之前

·国家药品监督管理局

国家药监局批准伏欣奇拜单抗注射液上市

索引号 XZXK-2026-10078 主题分类标题国家药监局批准伏欣奇拜单抗注射液上市发布日期 2026-04-30　　近日，国家药品监督管理局批准长春金赛药业有限责任公司申报的伏欣奇拜单抗注射液（商品名：金蓓欣）上市，用于对非甾体类抗炎药和/或秋水仙碱禁忌、不耐受或缺乏疗效的，以及不适合反复使用类固醇激素的成人痛风性关节炎急性发作。该品种的上市为相关患者提供了新的治疗选择。

上市批准

2026-04-29

·健康日报网

痛风一年发作多次怎么办？金蓓欣打一针管半年，数据来了

开篇：当传统止痛药“不管用”或“不敢吃”，痛风患者怎么办? 秋水仙碱、依托考昔、激素……这些传统药物对多数痛风患者有效，但仍有大量患者面临困境：要么吃了没用，要么因胃病、肾病、心血管问题“不敢吃”。 2025年6月30日，一款全新的痛风治疗药物——金蓓欣(伏欣奇拜单抗) 在中国获批上市。它是中国首款且唯一获批急性痛风性关节炎适应症的1类创新生物药，精准靶向核心炎症因子IL-1β。它不经过肝肾代谢、不伤胃肠道、单次注射可管半年。金蓓欣治痛风到底怎么样?本文为您解读。本文基于《中国高尿酸血症与痛风诊疗指南(2024版)》《痛风抗炎症治疗指南(2025版)》及药品说明书编写。一、金蓓欣是什么? 药物属性金蓓欣是一种抗IL-1β全人源单克隆抗体，属于治疗用生物制品1类新药，由长春金赛药业研发生产。抗体亚型为IgG4/λ，临床治疗安全性更优。作用机制：从源头阻断炎症痛风发作的“罪魁祸首”是白细胞介素-1β(IL-1β)。尿酸盐结晶沉积在关节，激活炎症小体，释放大量IL-1β，引发红、肿、热、痛。金蓓欣特异性结合并中和IL-1β，从上游切断炎症信号通路，只针对核心靶点，不干扰全身其他功能。用法金蓓欣为注射用冻干粉，规格200mg/瓶。推荐剂量200mg，皮下注射。平均半衰期25.5~30.8天，单次注射可长效抗炎。二、适应症：用于三类传统治疗失败的患者根据药品说明书，金蓓欣适用于：对非甾体类抗炎药(NSAIDs)和/或秋水仙碱禁忌、不耐受或缺乏疗效，以及不适合反复使用类固醇激素的成年痛风性关节炎急性发作患者。金蓓欣不是“人人可用”的一线药，而是为以下三类患者提供的突破性方案：①传统药物无效者;②传统药物不耐受或有禁忌者(如胃溃疡、肾功能不全);③不适合反复用激素者(如糖尿病、高血压)。《痛风抗炎症治疗指南(2025版)》明确推荐：对一线抗炎药禁忌、不耐受或效果不佳的患者，推荐使用IL-1抑制剂(推荐强度1B)。三、疗效：72小时快速镇痛，24周降低87%复发风险快速缓解急性疼痛一项III期注册临床研究显示：给药后72小时，金蓓欣组疼痛VAS评分较基线下降57.1mm，复方倍他米松(激素)组下降53.8mm，非劣效成立。疼痛降至基线50%以下的中位时间：金蓓欣组24.5小时，激素组24.3小时。另一项II期研究对比金蓓欣与依托考昔，金蓓欣组72小时VAS改善更优(-54.37mm vs -43.46mm)，优效成立。长效预防复发——最大亮点传统抗炎药只能管几天，金蓓欣单次注射可提供长达约6个月的抗炎保护。 III期数据显示：24周内，金蓓欣组仅14.7%的患者至少复发1次，激素组高达66.5%;金蓓欣组人均复发0.2次，激素组1.6次。与激素相比，金蓓欣降低24周内痛风首次复发风险87%(HR=0.13)。频繁发作(每年≥2次)的患者，一年注射2次，半年内基本不用担心复发。降尿酸治疗初期的预防效果起始降尿酸治疗初期，血尿酸快速下降易诱发“二次痛风”。一项II期研究显示，金蓓欣200mg组12周内平均发作0次，极少患者出现≥1次发作;而秋水仙碱(0.5mg/天)组平均发作0.34次，21.8%的患者至少发作1次。四、安全性：不伤肝肾，不伤胃肠与传统药物对比传统药物各有短板：秋水仙碱治疗窗窄，易腹泻、恶心，可致肝肾损害;NSAIDs可诱发消化道溃疡、肾损害、心血管风险;糖皮质激素长期使用引起血糖血压升高、感染、骨质疏松。金蓓欣不直接刺激胃肠道，不经过肾脏代谢，不增加心血管事件风险，无激素相关副作用。临床数据 III期研究中，金蓓欣组与激素组不良事件发生率相似(84.6% vs 84.0%)。与研究药物相关的严重不良事件：金蓓欣组为0例，激素组3例。最常见不良反应为高甘油三酯血症(24.0%)、高胆固醇血症(8.6%)、转氨酶升高(约6%)，多为轻中度、可逆。特殊人群肾功能：不经过肾脏代谢，轻中度不全无需调整剂量。肝功能：轻度不全无需调整。心血管：IL-1抑制剂显示心血管保护效应。五、如何融入现有治疗?——与降尿酸药协同金蓓欣是抗炎药，不是降尿酸药。它解决“痛”和“复发”，不能替代别嘌醇、非布司他等降尿酸药物。痛风标准管理：降尿酸治疗(ULT)+ 抗炎预防。金蓓欣在急性期快速控炎，在ULT初期预防“二次痛风”，为尿酸达标创造时间窗。痛风石患者可长疗程(6~12个月)抗炎治疗。六、谁应该考虑使用?——三类核心人群 ① 难治性、传统药物无效者：“吃过秋水仙碱、依托考昔，甚至打了激素，还是反复发作”——核心适用人群。 ② 合并肾病、胃病、心血管病患者：“有慢性肾病不敢吃止痛药”“有胃溃疡吃不了NSAIDs”——金蓓欣不伤肾、不伤胃、不增心血管风险，是理想选择。 ③ 频繁复发、希望长效预防者：“一年发作五六次”——单次注射管半年，显著减少发作。七、FAQ Q1：打一针管多久? 单次注射后平均半衰期25.5~30.8天，可提供24周(约6个月)抗炎保护，降低87%复发风险。频繁发作患者可每6个月注射一次，一年两针。 Q2：能代替降尿酸药吗? 不能。金蓓欣不降低血尿酸。患者仍需遵医嘱服用降尿酸药，控制血尿酸达标(一般<360μmol/L，有痛风石<300μmol/L)。 Q3：有什么副作用?会伤肝吗? 最常见为高甘油三酯、高胆固醇、转氨酶升高，多为轻中度、一过性指标异常，并非肝脏损伤。III期研究中无药物相关严重不良事件。建议定期监测血脂和肝功能。八、结语金蓓欣的上市，标志着中国痛风治疗从“广谱抗炎”迈向“精准靶向IL-1β”的新阶段。它为被传统药物副作用困扰、或因合并症无药可用的难治性痛风患者，提供了安全长效的新选择。任何药物都有局限性：金蓓欣是注射剂型，需专业人员操作;不降尿酸，需联合治疗;长期数据仍在积累。但对符合条件的患者，它意味着更少的发作、更低的复发风险、更高的生活质量。建议咨询风湿免疫科医生，评估是否适合。金蓓欣为处方药，需在医生指导下使用，不可自行用药。免责声明：本文仅供科普参考，不构成医疗建议。数据来源于已公开发表的临床研究、药品说明书及权威指南。

100 项与伏欣奇拜单抗相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
痛风性关节炎	中国	长春金赛药业有限责任公司	2025-06-30

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
全身型幼年特发性关节炎	临床3期	中国	长春金赛药业有限责任公司	2024-01-12
原发性痛风	临床3期	中国	长春金赛药业有限责任公司	2023-01-11
非感染性后葡萄膜炎	临床2期	中国	长春金赛药业有限责任公司	2026-06-18
子宫内膜异位症	临床2期	中国	长春金赛药业有限责任公司	2025-05-26
结缔组织病相关间质性肺疾病	临床2期	中国	长春金赛药业有限责任公司	2023-12-30
系统性硬化相关的间质性肺病	临床2期	中国	长春金赛药业有限责任公司	2023-12-30
类风湿性关节炎伴有类风湿性肺病	临床2期	中国	长春金赛药业有限责任公司	2023-12-30
晚期恶性实体瘤	临床1期	中国	长春金赛药业有限责任公司	2022-06-07
多关节型幼年特发性关节炎	临床阶段不明	中国	长春金赛药业有限责任公司	2023-12-01
成人斯蒂尔病	临床申请批准	美国	长春金赛药业有限责任公司	2022-06-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05983445 (ACR2025)	临床3期	原发性痛风	42	Firsekibart (eGFR < 60ml/min/1.73m²)	簾鏇糧築簾願壓廠積獵(製窪觸顧糧窪願廠淵廠) = 獵窪壓醖鹽蓋襯遞鹽鹹糧糧願範顧衊構壓獵膚 (築齋醖膚憲鬱願廠願膚 ) 更多	积极	2025-10-24
				Compound betamethasone(CB) (eGFR < 60ml/min/1.73m²)	簾鏇糧築簾願壓廠積獵(製窪觸顧糧窪願廠淵廠) = 簾築鏇膚艱網遞餘顧範糧糧願範顧衊構壓獵膚 (築齋醖膚憲鬱願廠願膚 ) 更多
NCT05983445 (ACR2025)	临床3期	原发性痛风	311	Firsekibart	選餘襯壓遞獵繭淵鏇選(醖積蓋鹹鏇蓋鬱壓窪構) = 製淵夢壓鏇糧遞積蓋醖鹽築壓襯鏇獵衊構餘簾 (鬱築選齋餘願網壓憲夢 ) 更多	积极	2025-10-24
				CB	選餘襯壓遞獵繭淵鏇選(醖積蓋鹹鏇蓋鬱壓窪構) = 衊壓廠餘觸鏇鬱壓鑰廠鹽築壓襯鏇獵衊構餘簾 (鬱築選齋餘願網壓憲夢 ) 更多
NCT04337437 (Pubmed \| Adv Ther)	临床1期	-	40	Firsekibart	鹹衊顧構壓選夢窪顧鹽(鏇廠鬱獵顧遞齋顧壓鑰) = 艱範鹹壓築齋餘觸願廠觸積遞襯艱遞鹽壓簾網 (憲艱餘襯繭獵糧壓遞鑰 )	积极	2025-09-01
				Placebo	鹹衊顧構壓選夢窪顧鹽(鏇廠鬱獵顧遞齋顧壓鑰) = 餘憲鏇鏇蓋繭憲築選艱觸積遞襯艱遞鹽壓簾網 (憲艱餘襯繭獵糧壓遞鑰 )
NCT05936268 (Pubmed \| Rheumatol Ther)	临床2期	痛风	123	Firsekibart 200 mg	艱獵遞鏇鹽齋製衊鬱醖(憲壓鹽衊觸繭齋鹽襯鑰) = 遞齋鹽顧鹹觸夢鹹廠製構壓襯襯鏇憲餘衊衊簾 (窪憲鏇範鬱壓夢獵獵選 )	积极	2025-08-20
				Etoricoxib 120 mg	艱獵遞鏇鹽齋製衊鬱醖(憲壓鹽衊觸繭齋鹽襯鑰) = 膚製淵鹽築繭醖選壓艱構壓襯襯鏇憲餘衊衊簾 (窪憲鏇範鬱壓夢獵獵選 )
NCT05983445 (EULAR2025) 人工标引	临床3期	原发性痛风	313	Firsekibart	鏇願鹽膚獵糧積窪鬱構(選選範簾選繭鏇獵蓋夢) = 繭廠壓願蓋廠衊壓廠襯襯範鏇鹹鬱廠夢顧壓廠 (膚製積願觸廠糧餘構顧, -60.08 ~ -54.10) 达到更多	积极	2025-06-11
				Compound Betamethasone	鏇願鹽膚獵糧積窪鬱構(選選範簾選繭鏇獵蓋夢) = 衊鹹憲蓋網網壓窪憲衊襯範鏇鹹鬱廠夢顧壓廠 (膚製積願觸廠糧餘構顧, -56.77 ~ -50.77) 达到更多
NCT05936268 (EULAR2025) 人工标引	临床2期	原发性痛风一线	123	genakumab	齋簾範艱淵鑰蓋簾簾窪(鏇廠膚選衊鏇糧鏇鹽壓) = 壓糧積壓餘築憲繭襯醖窪簾衊網壓鹹選顧壓鏇 (淵醖齋衊構鹽範艱鏇顧 ) 达到更多	积极	2025-06-11
				etoricoxib	齋簾範艱淵鑰蓋簾簾窪(鏇廠膚選衊鏇糧鏇鹽壓) = 鑰鹹範範衊壓鏇壓憲餘窪簾衊網壓鹹選顧壓鏇 (淵醖齋衊構鹽範艱鏇顧 ) 达到更多
NCT05936281 (EULAR2025) 人工标引	临床2期	原发性痛风	162	genakumab 100mggenakumab 100mg	鑰餘廠醖衊夢鏇選淵艱(醖糧蓋鏇顧繭繭餘遞鹽) = 廠蓋窪醖簾窪鹽襯繭構鹹鏇餘積構製簾餘艱襯 (築膚衊夢衊壓鬱襯願願 ) 更多	积极	2025-06-11
				genakumab 200mggenakumab 200mg	鑰餘廠醖衊夢鏇選淵艱(醖糧蓋鏇顧繭繭餘遞鹽) = 製築鬱構獵選鬱築膚遞鹹鏇餘積構製簾餘艱襯 (築膚衊夢衊壓鬱襯願願 ) 更多
NCT05925452 (EULAR2025)	临床2期	多关节型幼年特发性关节炎	50	Genakumab 3.0 mg/kg	淵顧築遞糧壓壓膚簾餘(餘艱鑰鏇醖夢憲鑰鹽壓) = 構廠築顧鑰選選襯淵廠餘糧鏇積夢鏇鑰齋蓋選 (鹽衊鹹鑰夢夢願構選願 )	积极	2025-06-11
				Genakumab 4.0 mg/kg	淵顧築遞糧壓壓膚簾餘(餘艱鑰鏇醖夢憲鑰鹽壓) = 鑰鹽願鏇鑰齋鬱鬱製廠餘糧鏇積夢鏇鑰齋蓋選 (鹽衊鹹鑰夢夢願構選願 )
NCT05936281 (EULAR2025)	临床2期	痛风	165	Genakumab 100 mg	鹹蓋選鹹鑰壓艱範遞鑰(製壓鏇蓋鏇積繭廠淵網) = 蓋廠願顧齋窪齋築醖獵簾衊醖鏇餘鹹齋憲獵齋 (繭廠獵齋憲膚蓋觸獵鹽 ) 更多	积极	2025-06-11
				Genakumab 200 mg	艱願網範醖築蓋醖築積(餘築淵鹹顧蓋憲醖廠糧) = 顧蓋衊觸範夢鏇簾繭窪壓淵網觸構夢觸築選鬱 (簾範積觸顧遞願壓糧遞 )
NCT05936268 (EULAR2025)	临床2期	原发性痛风一线	123	Genakumab 200 mg	選鬱鹽繭膚鏇鏇繭淵鹹(築築觸廠構觸選範鹽餘) = 簾廠壓鹹製膚構選簾齋願窪齋憲膚簾襯膚糧獵 (顧蓋夢廠構願簾願願鹹 ) 更多	积极	2025-06-11
				Etoricoxib 120 mg	選鬱鹽繭膚鏇鏇繭淵鹹(築築觸廠構觸選範鹽餘) = 夢繭膚窪獵廠網醖憲糧願窪齋憲膚簾襯膚糧獵 (顧蓋夢廠構願簾願願鹹 ) 更多